131 related articles for article (PubMed ID: 10836282)
21. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
Bogetto F; Bellino S; Vaschetto P; Ziero S
Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
[TBL] [Abstract][Full Text] [Related]
22. An open trial of olanzapine in the treatment of patients with psychotic depression.
Nelson EB; Rielage E; Welge JA; Keck PE
Ann Clin Psychiatry; 2001 Sep; 13(3):147-51. PubMed ID: 11791952
[TBL] [Abstract][Full Text] [Related]
23. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
[TBL] [Abstract][Full Text] [Related]
24. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
Lindenmayer JP; Volavka J; Lieberman J; Sheitman B; Citrome L; Chakos M; Czobor P; Parker B; Iskander A
J Clin Psychopharmacol; 2001 Aug; 21(4):448-53. PubMed ID: 11476131
[TBL] [Abstract][Full Text] [Related]
25. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study.
Mozes T; Greenberg Y; Spivak B; Tyano S; Weizman A; Mester R
J Child Adolesc Psychopharmacol; 2003; 13(3):311-7. PubMed ID: 14642019
[TBL] [Abstract][Full Text] [Related]
26. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents.
Kumra S; Jacobsen LK; Lenane M; Karp BI; Frazier JA; Smith AK; Bedwell J; Lee P; Malanga CJ; Hamburger S; Rapoport JL
J Am Acad Child Adolesc Psychiatry; 1998 Apr; 37(4):377-85. PubMed ID: 9549958
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome.
McCracken JT; Suddath R; Chang S; Thakur S; Piacentini J
J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):501-8. PubMed ID: 18928414
[TBL] [Abstract][Full Text] [Related]
28. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.
Potenza MN; Holmes JP; Kanes SJ; McDougle CJ
J Clin Psychopharmacol; 1999 Feb; 19(1):37-44. PubMed ID: 9934941
[TBL] [Abstract][Full Text] [Related]
29. Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up.
Karagianis JL; LeDrew KK; Walker DJ
Curr Med Res Opin; 2003; 19(6):473-80. PubMed ID: 14594518
[TBL] [Abstract][Full Text] [Related]
30. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.
Bitter I; Dossenbach MR; Brook S; Feldman PD; Metcalfe S; Gagiano CA; Füredi J; Bartko G; Janka Z; Banki CM; Kovacs G; Breier A;
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):173-80. PubMed ID: 14687871
[TBL] [Abstract][Full Text] [Related]
31. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
Poyurovsky M; Isaacs I; Fuchs C; Schneidman M; Faragian S; Weizman R; Weizman A
Am J Psychiatry; 2003 Feb; 160(2):297-302. PubMed ID: 12562576
[TBL] [Abstract][Full Text] [Related]
32. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch NC; Stikovac DM; Lewis SJ
J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
[TBL] [Abstract][Full Text] [Related]
33. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.
Tollefson GD; Dellva MA; Mattler CA; Kane JM; Wirshing DA; Kinon BJ
J Clin Psychopharmacol; 1999 Oct; 19(5):435-43. PubMed ID: 10505585
[TBL] [Abstract][Full Text] [Related]
34. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial.
Berk M; Ichim L; Brook S
Int Clin Psychopharmacol; 1999 Nov; 14(6):339-43. PubMed ID: 10565800
[TBL] [Abstract][Full Text] [Related]
35. Ondansetron treatment in patients with Tourette's syndrome.
Toren P; Laor N; Cohen DJ; Wolmer L; Weizman A
Int Clin Psychopharmacol; 1999 Nov; 14(6):373-6. PubMed ID: 10565805
[TBL] [Abstract][Full Text] [Related]
36. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
37. Ondansetron treatment in Tourette's disorder: a 3-week, randomized, double-blind, placebo-controlled study.
Toren P; Weizman A; Ratner S; Cohen D; Laor N
J Clin Psychiatry; 2005 Apr; 66(4):499-503. PubMed ID: 15816793
[TBL] [Abstract][Full Text] [Related]
38. An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania.
Stewart RS; Nejtek VA
J Clin Psychiatry; 2003 Jan; 64(1):49-52. PubMed ID: 12590623
[TBL] [Abstract][Full Text] [Related]
39. Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and Adolescents.
Sallee F; Kohegyi E; Zhao J; McQuade R; Cox K; Sanchez R; van Beek A; Nyilas M; Carson W; Kurlan R
J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):771-781. PubMed ID: 28686474
[TBL] [Abstract][Full Text] [Related]
40. Does olanzapine have antidepressant properties? A retrospective preliminary study.
Ghaemi SN; Cherry EL; Katzow JA; Goodwin FK
Bipolar Disord; 2000 Sep; 2(3 Pt 1):196-9. PubMed ID: 11256687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
